METABOLIC DISORDERS IN PATIENTS WITH ONCOLOGIC PATHOLOGY

Raisa A. Aringazina, Nurgul Zholdassova, Zhansulu Nurgaliyeva, Bakhtiyar Kurmanalin, Indira Kaibagarova

2022

Closed access Metadata (CSL-JSON)
DOI 10.52532/2663-4864-2022-3-65-19-23
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Relevance: Metabolic disorders often take on a systemic character. It affects carbohydrate, lipid, and hormonal metabolism. Moreover, these changes promote the development and aggravation of several pathologies. The prevalence of metabolic disorders, including obesity, is increasing worldwide and in Kazakhstan. The study focused on the clinical characteristics of metabolic syndrome (MS) components in patients with cancer comorbidities. Methods: The materials included medical records of cancer patients with MS – 35 people (main group) and non-cancerous patients with MS – 35 people (control group). MS was diagnosed with a combination of three symptoms: abdominal obesity, high blood pressure, and increased high-density lipoprotein cholesterol (HDL-C) levels. The data were analyzed and processed using the STATIS-TICA 10 software package. The significance criterion was p<0.05. Results: All studied patients were diagnosed with abdominal obesity. Indicators analysis showed a significant difference in HDL-C concentration in the main and control groups: 3.8 mmol/L in cancer patients and 5.7 mmol/L in the controls. No significant difference in blood pressure was found. Conclusion: The age of patients with MS evidences a threatening tendency to develop metabolic disorders in young and middle ages. A significantly lower concentration of LDL-C in cancer patients compared with the controls allows using this parameter to predict cancer ]development in patients diagnosed with MS. Thus, HDL-C concentration could be used as a metabolic marker for pre-symptomatic diagnostics.